Beggs, P W <br/><br/>
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).  [electronic resource] 

 -  British journal of clinical pharmacology  Jan 1999 
 - 99-104 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0306-5251 
<br/><br/><label>Standard No.: </label>10.1046/j.1365-2125.1999.00846.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Bezafibrate--adverse effects<br/>Cohort Studies<br/>Comorbidity<br/>Diabetes Complications<br/>Female<br/>Gemfibrozil--adverse effects<br/>Humans<br/>Hypertension--complications<br/>Lipids--blood<br/>Male<br/>Myocardial Ischemia--prevention & control<br/>New Zealand<br/>Practice Patterns, Physicians'<br/>Product Surveillance, Postmarketing--methods<br/>Random Allocation<br/>Retrospective Studies<br/>Risk Factors<br/>Simvastatin--adverse effects<br/>Surveys and Questionnaires<br/>Treatment Outcome